Area of research
Hematology · Genetics
Research interest
Research interests include Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort
Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma
Retrospective study on pomalidomide‐<scp>PACE</scp> as a salvage regimen in aggressive relapsed and refractory multiple myeloma
The German Network for Personalized Medicine to enhance patient care and translational research
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
Telomere biology disorders may manifest as common variable immunodeficiency (CVID)
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for <i>CSNK1A1</i> in clonal expansion
Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie
<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
Differential impact of <i>IDH1</i>/<i>2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study
Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry
Dexamethasone nanomedicines for COVID-19
Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation
Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia